# A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

> **NCT06469281** · PHASE1 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 90 (estimated)

## Conditions studied

- Epithelial Ovarian Cancer
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer

## Interventions

- **OTHER:** 27T51
- **DRUG:** Cemiplimab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06469281
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-06
- **Primary completion:** 2030-05-27
- **Final completion:** 2030-05-27
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06469281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06469281, "A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06469281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*